Skip to Content
SurgeriesSurgeries
  • Conference Report
  • Open Access

17 November 2026

9 Pages

Machine Perfusion Across Solid Organ and Vascularized Composite Allograft Transplantation: Updates from the 2026 American Transplant Congress

,
,
and
1
Division of Transplant Surgery, Department of Surgery, The University of Oklahoma College of Medicine, Oklahoma City, OK 73104, USA
2
Dodge Family College of Arts and Sciences, The University of Oklahoma, Norman, OK 73019, USA
*
Author to whom correspondence should be addressed.

Abstract

The 2026 American Transplant Congress, jointly organized by the American Society of Transplant Surgeons and the American Society of Transplantation, highlighted the expanding role of machine perfusion (MP) in broadening the donor pool across liver, kidney, lung, heart, and vascularized composite allograft transplantation. Of 106 relevant abstracts identified, 39 with the greatest clinical and translational relevance were selected for discussion. Across organ systems, normothermic and hypothermic MP facilitated utilization of higher-risk grafts, including donation-after-circulatory-death, steatotic, and extended-criteria organs, with early outcomes comparable or superior to static cold storage. Normothermic regional perfusion emerged as a complementary preconditioning strategy, particularly in reducing biliary complications after liver transplantation and delayed graft function after kidney transplantation. Novel biomarkers, including perfusate flavin mononucleotide, and integrated biochemical, physiologic, and histologic panels showed promise for real-time graft viability assessment. Emerging approaches, including 7-day liver preservation, ischemia-free liver transplantation, gaseous cardiac perfusion, and ex situ modeling of T-cell-mediated rejection, further suggest that MP is evolving into a therapeutic and investigative platform. Important limitations include variable benefits across recipient risk profiles, cardiac size-matching constraints, and disparities in access to normothermic liver perfusion. Multicenter validation, equitable access, and organ- and risk-specific strategies will be essential to realize the full potential of MP in transplantation.

1. Introduction

The American Transplant Congress (ATC), jointly organized by the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (AST), serves as a premier platform for clinicians, researchers, and healthcare professionals to address the challenges of end-organ failure and to highlight clinical advances and innovations in transplantation.
The push toward machine perfusion reflects a persistent organ shortage: more than 103,000 candidates remained on the U.S. transplant waiting list in 2024, and donation-after-circulatory-death and other extended-criteria organs are being used more than ever to close that gap [1]. Over the past five years, several randomized trials have shown that machine perfusion performs as well as, or better than, static cold storage. Hypothermic oxygenated perfusion lowered rates of non-anastomotic biliary stricture after donation-after-circulatory-death liver transplantation [2]; the multicenter OCS Liver PROTECT trial found that normothermic perfusion reduced early allograft dysfunction and organ discard [3]; and a UK-wide randomized trial showed that normothermic kidney perfusion reduced delayed graft function after donation-after-circulatory-death transplantation [4]. Other groups have pushed the technology further still. Ischemia-free liver transplantation avoids cold and warm ischemia altogether by keeping the organ under continuous ex vivo perfusion from procurement through implantation [5], and one perfusion platform has kept an injured human liver viable outside the body for a full week [6], early signs that machine perfusion is becoming a tool for organ repair, not just preservation. Normothermic regional perfusion has likewise gained traction as a preconditioning strategy, with evidence that it reduces biliary complications after donation-after-circulatory-death liver transplantation [7]; an organ care system has extended heart transplantation to donation-after-circulatory-death donors with outcomes similar to donation after brain death [8]; and ex vivo lung perfusion has safely broadened the use of marginal and donation-after-circulatory-death lungs [9]. Access to these technologies, however, is not distributed evenly, and that disparity is drawing increasing attention in the literature [10].
This review summarizes oral and poster presentations focused on machine perfusion in liver, kidney, lung, heart, and vascularized composite allograft (VCA) transplantation. Of 106 abstracts identified, 39 with the greatest clinical relevance were selected for discussion [11]. Collectively, these studies highlight the expanding role of machine perfusion in improving graft viability, broadening the donor pool, and reducing waitlist mortality.

2. Liver

Liver-focused abstracts at this year’s Congress emphasized normothermic machine perfusion (NMP) as an increasingly mainstream preservation strategy, with a growing body of large registry and single-center data supporting its capacity to safely expand utilization of marginal, donation after circulatory death (DCD), and steatotic grafts—alongside emerging work on hypothermic oxygenated perfusion (HOPE), normothermic regional perfusion (NRP), and next-generation strategies aimed at eliminating ischemia–reperfusion injury altogether.
Brar et al. (University of Connecticut) analyzed a national SRTR cohort of 38,295 adult liver transplant recipients from 2019–2023 and found that NMP was associated with improved early post-transplant outcomes compared with static cold storage (SCS), despite being used more frequently for DCD grafts. NMP was associated with significantly higher 1- and 2-year patient survival and a lower 1-year graft failure rate, while outcomes at 3 years were comparable between groups. After adjustment for donor and recipient factors, NMP remained independently associated with reduced mortality at 1 and 2 years, suggesting a meaningful early survival benefit that may support broader utilization of marginal organs without compromising long-term outcomes. In a related analysis of the same SRTR cohort, Brar et al. found that NMP was used in only 5.8% of transplants and was disproportionately distributed across patient populations: non-Hispanic Black recipients and those with public insurance were significantly less likely to receive NMP, while patients with hepatocellular carcinoma, MELD exceptions, longer waitlist times, and lower MELD scores were more likely to receive an NMP-preserved graft—indicating that access to this technology remains uneven despite its potential to expand marginal graft utilization.
Nishimagi et al. (Henry Ford) examined 182 DCD liver transplants and found that large graft size (graft-to-recipient weight ratio ≥ 2.5) was associated with a higher incidence of early allograft dysfunction (EAD), a risk substantially reduced with NMP, with notable reductions among large grafts (27.6% vs. 70.8%). NMP was also associated with lower postoperative lactate levels, fewer reoperations, and elimination of primary nonfunction, with 90-day graft survival reaching 100% in both NMP groups. Subramanian et al. (Tampa General) compared 526 consecutive universal NMP cases with 518 historical cold-storage cases, finding that NMP enabled greater utilization of higher-risk grafts, including older donors and DCD livers, while increasing overall transplant volume by 86%. Despite the higher-risk graft profile, NMP was associated with lower transfusion requirements, less acute kidney injury, less EAD, and fewer non-anastomotic biliary strictures, with similar overall survival compared with cold storage; universal NMP also dramatically increased daytime transplantation, reduced reported staff burnout, and lowered hospital costs.
Singhal et al. (Tampa General) evaluated drivers of organ discard among 731 donor livers undergoing back-to-base NMP; only 7% were ultimately discarded, most commonly demonstrating absent glucose utilization, persistently elevated lactate, markedly elevated AST/ALT, and impaired arterial flow, suggesting that an integrated multi-parameter assessment during NMP provides the most reliable approach to identifying nonviable grafts. In a separate retrospective study of 422 livers preserved with back-to-base NMP, Singhal et al. found that despite longer total preservation time, grafts with prolonged cold ischemia time (CIT) had similar rates of EAD, biliary complications, laboratory outcomes, and survival, although severe stage 3 acute kidney injury was more common (35% vs. 17%)—suggesting NMP may mitigate the adverse effects traditionally associated with prolonged CIT.
Ranjbarian et al. (UC San Diego) performed serial protocol biopsies on 130 NMP liver allografts and found that allografts maintained histologic integrity throughout NMP and post-reperfusion, with necrosis rare or minimal. Satish et al. (Cleveland Clinic) evaluated perfusate flavin mononucleotide (FMN) as a marker of mitochondrial injury in 310 livers undergoing NMP; FMN at 4 h was the strongest predictor of graft loss compared with traditional viability markers, with levels ≥ 1.5 µg/mL associated with higher rates of biliary strictures within 1 year. Shahrestani et al. (Mount Sinai) studied 146 DCD liver transplant recipients and found NRP provided the strongest protection against biliary complications, with no ischemic cholangiopathy, strictures, or leaks in the NRP-based group; adding NMP after NRP did not diminish this protective effect, supporting NRP as a preferred preservation strategy with ex situ NMP as a useful adjunct.
Avedikian et al. (Henry Ford) found that NMP in DCD recipients appeared to mitigate several traditional donor-related risk factors for EAD, including older donor age, male donor sex, and macrovesicular steatosis ≥ 5%, though donor BMI remained a significant risk factor even with NMP. Karakaya et al. (Cleveland Clinic) evaluated the feasibility of prolonged HOPE using 24 discarded human livers perfused for up to 12–24 h, finding no significant deterioration in mitochondrial function or tissue injury compared with standard 4 h perfusion, suggesting extended HOPE may offer important logistical flexibility including daytime transplantation. Henriquez et al. (Western Michigan) examined whether prolonged NMP beyond 12 h was associated with increased complications among 371 liver transplant recipients (141 receiving NMP-preserved grafts); no significant differences were observed in early rejection, biliary strictures, or length of stay between grafts perfused for less than versus greater than 12 h.
Xiaoshun et al. (Sun Yat-sen University) compared ischemia-free liver transplantation (IFLT) with NMP in 144 recipients and found significantly lower rates of EAD with IFLT (15.3% vs. 44.4%) and a lower 1-year complication burden, along with improved 1-year patient and graft survival that persisted among recipients of extended-criteria donor grafts. Hofmann et al. (Innsbruck) developed and validated a long-term NMP protocol using an unmodified commercial perfusion system to preserve donor livers for up to 7 days; after iterative protocol refinement in porcine livers, stable liver function and structural integrity were maintained for 7 days, with successful application in non-transplanted human livers for a median of 135 h, demonstrating the feasibility of prolonged ex situ preservation for future graft regeneration and expanded utilization of marginal donor livers. Finally, McCabe et al. (University of Rochester) examined how NMP adoption since 2021 has affected living donor liver transplantation (LDLT) using UNOS data from 2018–2024; although the proportion of LDLT remained relatively stable across low-, intermediate-, and high-volume centers, the number of centers discontinuing LDLT (9) exceeded the number establishing new LDLT programs (8) in the post-NMP era, suggesting that increased deceased-donor organ availability through NMP may be subtly shifting practice patterns away from living donation.

3. Kidney

Kidney abstracts this year centered on refining viability assessment during machine perfusion, clarifying the specific patient and graft subgroups that benefit most from NRP and NMP, and exploring novel perfusate compositions and monitoring technologies to further expand safe utilization of extended-criteria and DCD kidneys.
Souza et al. (Johns Hopkins) assessed the effect of NRP on kidney graft injury using paired urine samples from 14 DCD donors, drawn before withdrawal of life support and again at cross-clamp. Urine creatinine–indexed albumin, the injury marker MCP-1, and the inflammatory marker IL-6 were all significantly increased at cross-clamp compared with initiation of heparin, while all other markers remained unchanged, suggesting NRP could mitigate graft injury associated with transplantation. Nakayama et al. (Stanford) retrospectively evaluated terminal renal resistance (RR) as a marker of graft quality among 36,490 kidney transplants performed with hypothermic machine perfusion (HMP) between 2015 and 2023; the negative impact of high RR on 5-year graft survival was modest in grafts with KDPI < 0.35 and strongest in grafts with KDPI > 0.85, with an estimated 357 additional grafts that could have been utilized had grafts with KDPI ≤ 0.85 and RR ≥ 0.3 not been discarded.
Tu et al. (Sun Yat-sen University) investigated triple-knockout porcine red blood cells as an oxygen-carrying component for NMP of discarded extended-criteria human kidneys; kidneys maintained stable metabolic parameters without injury during this approach, while switching to human-blood reperfusion produced an increased inflammatory response, suggesting the porcine-cell approach is both safe and feasible with a possible advantage over conventional human-blood reperfusion. Oki et al. (Henry Ford) retrospectively assessed 13,853 mate-kidney pairs and found that older age, obesity, retransplantation, dialysis history, greater HLA mismatch, diabetes, frailty severity, and longer cold ischemia time were each associated with increased delayed graft function (DGF) risk, even though machine perfusion significantly reduced DGF overall compared with grafts preserved without it, with the notable exception of recipients with obesity.
Kusakabe et al. (Cleveland Clinic Florida) retrospectively evaluated 21,010 DCD kidney transplants performed between 2020 and 2025 and found NRP associated with decreased DGF incidence, shorter hospitalization, and significantly improved overall graft and patient survival, with the greatest benefit observed in higher-risk subgroups. Holzner et al. (Mount Sinai) found that centralized NMP rescue of discarded kidneys—despite higher KDPI and significantly longer cold ischemia time—achieved a significantly lower weighted percentage of DGF than non-NMP grafts from the same centers, with no significant difference in patient or graft survival. Asassfeh et al. (Medical College of Wisconsin) analyzed NRP use in DCD kidney transplants (2020–2025), comparing NRP (n = 1538) with non-NRP (n = 1950) kidneys; at 3 years, graft survival did not differ significantly between groups, but NRP was independently associated with lower DGF rates, and NRP use increased by 25% every 6 months during the study period.
Katz-Greenberg et al. (Duke) examined outcomes among 35 patients who received discarded kidney grafts re-allocated after undergoing NMP—most DCD, with a median KDPI of 86%—finding DGF and primary nonfunction in 31.4% and 14.3% of grafts, respectively, supporting NMP’s role in enabling transplantation of otherwise-discarded high-risk kidneys. Merola et al. (Cincinnati Children’s) developed a human model of kidney graft rejection by perfusing grafts with allogeneic human T cells via NMP for up to 4 days; kidneys began functioning within 2 h and continued for up to 4 days, with T-cell tissue infiltration noted by 12 h, offering a platform to study rejection mechanisms and test potential treatments.
Liang et al. (Mayo Clinic, Rochester) analyzed the effects of interrupted machine perfusion across 108,236 kidney transplants performed between 2014 and 2024; after adjustment for donor, recipient, and transplant factors, primary nonfunction was significantly more likely with interrupted perfusion than with either continuous machine perfusion or static cold storage, emphasizing the importance of maintaining continuous perfusion for optimal graft function. Crasta et al. (Cleveland Clinic) compared HOPE with NMP in deceased donor kidneys and found that FMN, used as an indicator of metabolic deterioration, was significantly higher in NMP grafts than HOPE grafts, with NMP kidneys showing more injury, glomerular congestion, and tubular swelling—suggesting HOPE may be superior to NMP with respect to graft injury.
Feeney et al. (Mount Sinai) implemented a novel pulsatile-flow pump during thoracoabdominal and abdominal NRP over 4 h; all organs performed well, with successful intestinal peristalsis, urine production, and cardiac contractility observed off-pump during thoracoabdominal NRP, and improved tissue viability after abdominal NRP. Lamsehchi et al. (Johns Hopkins) investigated flush pattern effectiveness using methylene blue dye in porcine kidneys gravity-flushed with 300–1000 mL of cold UW solution; dye distribution was uneven across all groups, concentrating in the renal cortex with minimal medullary penetration, suggesting flow rate rather than flush volume may be the more critical determinant of homogeneous perfusate distribution.

4. Lung

Lung abstracts highlighted growing sophistication of donor risk stratification and the expanding role of regional and ex vivo perfusion in safely utilizing marginal and DCD lungs.
Banga et al. applied a LightGBM machine learning model to 28,120 UNOS lung transplants and found marked mortality risk differences across diagnostic categories (11–50% at 1 year), with DCD and machine-perfused grafts generally increasing risk—suggesting preservation method effectiveness depends on recipient diagnosis and supporting dynamic, diagnosis-specific allocation scoring over a single generalized framework. Demarest et al. studied 143 DCD lung cases and found comparable outcomes during centralized ex vivo lung perfusion (EVLP) regardless of procurement strategy—traditional rapid recovery, abdominal NRP, or thoracoabdominal NRP—with similar conversion rates to transplantation (53–76%), supporting the safety of diverse retrieval techniques ahead of EVLP. Wijesinha et al. analyzed 15,530 U.S. lung transplants (2015–2021) and found EVLP associated with reduced elevated mortality risk otherwise seen with marginal donor lungs, supporting EVLP as an effective donor pool expansion strategy.

5. Heart

Heart-focused presentations this year reflected active innovation across multiple fronts—from novel biostasis and metabolic strategies aimed at extending preservation windows to device- and gas-based perfusion platforms designed to overcome the biomechanical and logistical limitations of current preservation approaches.
Al-Attar et al. investigated a novel biostasis cocktail designed to extend donor heart viability beyond the traditional 4–6 h limit. In a rodent model, donor hearts treated with the cocktail in University of Wisconsin solution were stored at 4 °C for 48 h, then assessed after 4 h of NMP; biostasis-treated hearts avoided arrhythmias, maintained lactate output and vascular resistance comparable to fresh controls, and preserved high tissue viability—outcomes superior to standard cold static storage, with controlled, delayed contractility during reperfusion appearing to promote ventricular recovery. Farr et al. analyzed 1848 heart transplants managed on the Organ Care System (OCS) to examine how donor-to-recipient predicted heart mass ratio (PHMr) influences severe primary graft dysfunction (PGD); a U-shaped relationship emerged, with the highest PGD risk occurring at very low (<0.80) and very high (>2.0) PHMr values, and PHMr proved a more accurate predictor of size mismatch than traditional weight- or height-based measurements, though OCS could not overcome the biomechanical limitations of severe anatomical mismatch.
Urban et al. evaluated normothermic oxygenated perfusion (NOPE) against HOPE for DCD hearts; both methods produced similar markers of cardiac and vascular injury overall, although the NOPE group showed significantly higher Troponin I levels and greater expression of proinflammatory mediators, suggesting the hypothermic environment of HOPE reduces metabolic demand and provides enhanced cellular protection. Andrijauskaite et al. evaluated the VP.S ENCORE® PEDS system for preserving pediatric donor hearts during 9 h of HOPE in a non-human primate study; hearts weighing as little as 41 g maintained stable weight, low lactate levels, and left ventricular contractility comparable to standard 4 h static cold storage controls, suggesting HOPE can safely double the preservation window for small pediatric hearts.
Hassanzadeh et al. investigated whether optimizing ex situ heart perfusion by lowering glucose and insulin concentrations could improve preservation; reducing glucose and insulin significantly decreased tissue edema and harmful signaling markers, though low glucose alone impaired cardiac function, while supplementing with ketones restored cardiac performance and maintained the reduction in edema, suggesting a shift toward ketone-based metabolism may better support the heart during ex situ perfusion. Finally, Makaev et al. demonstrated that the “HIPPER” high-pressure gaseous perfusion technique—using a pressurized oxygen–xenon gas mixture without liquid media—successfully scaled to preserve human-sized organs; despite an 8 h preservation period, twice the duration of the 4 h standard cold storage control, gas-perfused hearts achieved significantly better ventricular pressure recovery, enhanced lactate clearance, and required less functional support.

6. Vascularized Composite Allograft

Janjic and Gorantla (Duquesne University) found artificial oxygen carrier nanoparticles during NMP preserved intact neurovascular structures, reduced edema, prevented necrosis, and maintained endothelial barrier integrity in limb allografts, with transcriptomic analysis showing lower hypoxia and inflammatory markers—suggesting these nanoparticles may mitigate graft injury and improve VCA outcomes on NMP.

7. Discussion

Across all organ systems, this year’s Congress underscored that machine perfusion has moved into mainstream practice, with an expanding evidence base showing it can safely broaden the donor pool without compromising—and often improving—outcomes. Registry analyses in liver and kidney transplantation showed NMP- and NRP-preserved grafts, despite being drawn disproportionately from higher-risk donors, achieved outcomes comparable or superior to conventional preservation. This pattern recurred throughout: HOPE preserved mitochondrial and organ function well beyond traditional limits, EVLP extended safe utilization of marginal lungs, and novel biostasis, ketone-supplemented, and gaseous perfusion strategies pushed cardiac preservation past the traditional 4–6 h ceiling. That finding fits with the published trial data: both hypothermic and normothermic liver perfusion have shown outcomes comparable to, or better than, static cold storage even when higher-risk donor organs were used [3,4], and a UK-wide randomized trial found the same pattern for normothermic kidney perfusion, with lower rates of delayed graft function [5].
A second major theme was the maturation of NRP as a preconditioning strategy complementing rather than competing with ex situ perfusion—reducing biliary complications after liver transplantation and delayed graft function after kidney transplantation, with adoption increasing 25% every six months. Emerging tools including pulsatile NRP pumps, perfusate FMN as a real-time mitochondrial injury marker and integrated biochemical–physiologic–histologic panels signal a shift toward more precise, mechanistically grounded graft assessment. A 2024 systematic review and meta-analysis reached the same conclusion, confirming that normothermic regional perfusion lowers biliary complication rates after donation-after-circulatory-death liver transplantation [8].
These gains were not uniform. DGF risk remained elevated in recipients with obesity despite perfusion; heart mass mismatch remained a biomechanical limitation perfusion alone could not correct; and machine-perfused lung benefit varied by recipient diagnosis. Equity concerns emerged directly, with significantly lower NMP access among non-Hispanic Black recipients and publicly insured patients, and early signals suggested a possible contraction in living donor liver programs as deceased-donor availability expands. A 2024 analysis found the same unevenness, with unequal center-level access to normothermic liver perfusion and open-offer organs [11]. The cardiac size-matching problem is not new either: the pivotal donation-after-circulatory-death heart trial required careful donor-recipient matching even with perfusion support [9], and a post hoc analysis of the NOVEL trial likewise found that the benefit of lung perfusion varies by recipient diagnosis [10].
Finally, several forward-looking abstracts suggest machine perfusion is evolving from a preservation tool into a broader therapeutic platform. Seven-day liver preservation, ischemia-free transplantation, and ex situ modeling of T-cell-mediated rejection point toward a future enabling graft regeneration, targeted therapy, and mechanistic study of injury outside the recipient. Realizing this will require multicenter validation, equitable access, and tailoring of perfusion strategy by organ, donor risk, and recipient diagnosis rather than a single uniform approach. Recent proof-of-concept work already points in this direction: ischemia-free liver transplantation [6] and week-long ex vivo liver preservation [7] have both been demonstrated in humans, suggesting these platforms can be used for organ repair and study, not simply storage.
Read alongside this published literature, the 2026 Congress abstracts look less like a departure and more like an extension of where the field already stood. Earlier trials established that perfusion was feasible and at least as good as static cold storage [3,4,5,7,9]; this year’s presentations build on that with larger registries, mechanistic biomarkers, and organ-specific detail, while also putting numbers to access and equity gaps that published cohorts had only begun to describe [11]. The next step is to carry these conference findings through to peer-reviewed validation, as machine perfusion keeps moving from a preservation tool toward a therapeutic one [6,7].

8. Conclusions

This year’s American Transplant Congress reaffirmed that machine perfusion has become a central pillar of modern organ preservation, consistently enabling safer use of marginal and higher-risk grafts across every organ system while offering new tools for real-time graft assessment. NRP and ex situ perfusion increasingly function as complementary rather than competing strategies, reshaping how transplant centers evaluate, allocate, and utilize donor organs.
Continued progress will depend on multicenter validation of the biomarkers and protocols presented this year, deliberate attention to equitable access, and organ-, risk-, and diagnosis-specific tailoring of perfusion strategy. As these technologies mature from preservation tools into broader therapeutic platforms, they hold significant promise for further expanding the donor pool and improving outcomes across transplantation.

Author Contributions

Conceptualization—M.P.; Resources—M.P., K.L.W., H.M., H.N.; Writing—original draft preparation—K.L.W., H.M., H.N.; writing—review and editing—all authors; Final review, approval and supervision—M.P. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Acknowledgments

During the preparation of this work the authors used AI tools for formatting. After using these tools, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article.

Conflicts of Interest

The authors declare no competing interests.

Abbreviations

AKIAcute kidney injury
CITCold ischemia time
DCDDonation after circulatory death
DGFDelayed graft function
EADEarly allograft dysfunction
EVLPEx vivo lung perfusion
FMNFlavin mononucleotide
HLAHuman leukocyte antigen
HIPPERHigh-pressure perfusion
HOPEHypothermic oxygenated perfusion
HMPHypothermic machine perfusion
IFLTIschemia-free liver transplantation
KDPIKidney Donor Profile Index
LDLTLiving donor liver transplantation
MPMachine perfusion
NMPNormothermic machine perfusion
NOPENormothermic oxygenated perfusion
NRPNormothermic regional perfusion
OCSOrgan Care System
PGDPrimary graft dysfunction
PHMrPredicted heart mass ratio
SCSStatic cold storage
VCAVascularized composite allograft

References

  1. American Transplant Congress 2026. 2026. Available online: https://www.sciencedirect.com/journal/american-journal-of-transplantation/vol/26/issue/7/suppl/S1 (accessed on 1 July 2026).
  2. Health Resources and Services Administration. OPTN/SRTR 2024 Annual Data Report: Overview of U.S. Solid Organ Transplantation. 2024. Available online: https://srtr.hrsa.gov/adr/2024/Overview/ (accessed on 28 October 2026).
  3. van Rijn, R.; Karimian, N.; Matton, A.P.M.; Burlage, L.C.; Westerkamp, A.C.; van den Berg, A.P.; de Kleine, R.H.J.; de Boer, M.T.; Lisman, T.; Porte, R.J. Hypothermic Machine Perfusion in Liver Transplantation—A Randomized Trial. N. Engl. J. Med. 2021, 384, 1391–1401. [Google Scholar] [CrossRef] [Scilit]
  4. Markmann, J.F.; Abouljoud, M.S.; Ghobrial, R.M.; Bhati, C.S.; Pelletier, S.J.; Lu, A.D.; Ortiz, J.; Kim, J.; Vianna, R.M.; Elias, N.; et al. Impact of Portable Normothermic Blood-Based Machine Perfusion on Outcomes of Liver Transplant: The OCS Liver PROTECT Randomized Clinical Trial. JAMA Surg. 2022, 157, 189–198. [Google Scholar]
  5. Hosgood, S.A.; Callaghan, C.J.; Wilson, C.H.; Smith, L.; Mullings, J.; Mehew, J.; Oniscu, G.C.; Phillips, B.L.; Bates, L.; Nicholson, M.L. Normothermic Machine Perfusion versus Static Cold Storage in Donation after Circulatory Death Kidney Transplantation: A Randomized Controlled Trial. Nat. Med. 2023, 29, 1511–1519. [Google Scholar] [CrossRef] [Scilit]
  6. Guo, Z.; Zhao, Q.; Huang, S.; Huang, C.; Hu, Z.; Tao, Y.; Yang, Z.; Wang, D.; Ju, W.; Wang, L.; et al. Ischaemia-Free Liver Transplantation in Humans: A First-in-Human Trial. Lancet Reg. Health West. Pac. 2021, 16, 100260. [Google Scholar] [CrossRef] [Scilit]
  7. Eshmuminov, D.; Becker, D.; Bautista Borrego, L.; Hefti, M.; Schuler, M.J.; Hagedorn, C.; Muller, X.; Mueller, M.; Onder, C.; Graf, R.; et al. An Integrated Perfusion Machine Preserves Injured Human Livers for 1 Week. Nat. Biotechnol. 2020, 38, 189–198. [Google Scholar] [CrossRef] [Scilit]
  8. Mastrovangelis, C.; Frost, C.; Hort, A.; Laurence, J.; Pang, T.; Pleass, H. Normothermic Regional Perfusion in Controlled Donation after Circulatory Death Liver Transplantation: A Systematic Review and Meta-Analysis. Transpl. Int. 2024, 37, 13263. [Google Scholar] [CrossRef] [Scilit]
  9. Schroder, J.N.; Shah, A.; Pretorius, V.; Smith, M.A.; Richardson, W.S.; Hoffman, J.R.E.; Daneshmand, M.A.; Silvestry, S.; Goldstein, D.J.; Patel, C.B.; et al. Transplantation Outcomes with Donor Hearts after Circulatory Death. N. Engl. J. Med. 2023, 388, 2360–2370. [Google Scholar] [CrossRef] [Scilit]
  10. Gouchoe, D.A.; Sanchez, P.G.; D’Cunha, J.; Bermudez, C.A.; Daneshmand, M.A.; Davis, R.D.; Hartwig, M.G.; Wozniak, T.C.; Kon, Z.N.; Griffith, B.P.; et al. NOVEL and NOVEL Extension Trial Investigators. Ex Vivo Lung Perfusion in Donation after Circulatory Death: A Post-Hoc Analysis of the NOVEL Trial. J. Thorac. Cardiovasc. Surg. 2024, 168, 724–734.e7. [Google Scholar]
  11. Wehrle, C.J.; Gross, A.; Fares, S.; Kusakabe, J.; Calderon, E.; Shanmugarajah, K.; Uysal, M.; Fleischer, C.M.; Allkushi, E.; Schold, J.D.; et al. Changing Landscape of Open Offers in Liver Transplantation in the Machine Perfusion Era: Exposure, Equity, and Economics. Clin. Transplant. 2024, 38, e70012. [Google Scholar] [CrossRef] [Scilit]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Article metric data becomes available approximately 24 hours after publication online.